99 related articles for article (PubMed ID: 27373781)
1. Untargeted mass spectrometric approach in metabolic healthy offspring of patients with type 2 diabetes reveals medium-chain acylcarnitine as potential biomarker for lipid induced glucose intolerance (LGIT).
Knebel B; Mack S; Lehr S; Barsch A; Schiller M; Haas J; Lange S; Fuchser J; Zurek G; Müller-Wieland D; Kotzka J
Arch Physiol Biochem; 2016 Dec; 122(5):266-280. PubMed ID: 27373781
[TBL] [Abstract][Full Text] [Related]
2. Human serum acylcarnitine profiles in different glucose tolerance states.
Zhang X; Zhang C; Chen L; Han X; Ji L
Diabetes Res Clin Pract; 2014 Jun; 104(3):376-82. PubMed ID: 24837145
[TBL] [Abstract][Full Text] [Related]
3. Similarities in serum acylcarnitine patterns in type 1 and type 2 diabetes mellitus and in metabolic syndrome.
Bene J; Márton M; Mohás M; Bagosi Z; Bujtor Z; Oroszlán T; Gasztonyi B; Wittmann I; Melegh B
Ann Nutr Metab; 2013; 62(1):80-5. PubMed ID: 23296094
[TBL] [Abstract][Full Text] [Related]
4. Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans.
Wigger L; Cruciani-Guglielmacci C; Nicolas A; Denom J; Fernandez N; Fumeron F; Marques-Vidal P; Ktorza A; Kramer W; Schulte A; Le Stunff H; Liechti R; Xenarios I; Vollenweider P; Waeber G; Uphues I; Roussel R; Magnan C; Ibberson M; Thorens B
Cell Rep; 2017 Feb; 18(9):2269-2279. PubMed ID: 28249170
[TBL] [Abstract][Full Text] [Related]
5. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at?
Zhao X; Peter A; Fritsche J; Elcnerova M; Fritsche A; Häring HU; Schleicher ED; Xu G; Lehmann R
Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E384-93. PubMed ID: 19066319
[TBL] [Abstract][Full Text] [Related]
6. Plasma Acylcarnitines and Risk of Type 2 Diabetes in a Mediterranean Population at High Cardiovascular Risk.
Guasch-Ferré M; Ruiz-Canela M; Li J; Zheng Y; Bulló M; Wang DD; Toledo E; Clish C; Corella D; Estruch R; Ros E; Fitó M; Arós F; Fiol M; Lapetra J; Serra-Majem L; Liang L; Papandreou C; Dennis C; Martínez-González MA; Hu FB; Salas-Salvadó J
J Clin Endocrinol Metab; 2019 May; 104(5):1508-1519. PubMed ID: 30423132
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantification of cardiovascular disease related metabolic risk factors using liquid chromatography tandem mass spectrometry in human serum.
Wang M; Yang R; Dong J; Zhang T; Wang S; Zhou W; Li H; Zhao H; Zhang L; Wang S; Zhang C; Chen W
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1009-1010():144-51. PubMed ID: 26735710
[TBL] [Abstract][Full Text] [Related]
8. The effects of long- or medium-chain fat diets on glucose tolerance and myocellular content of lipid intermediates in rats.
De Vogel-van den Bosch J; Hoeks J; Timmers S; Houten SM; van Dijk PJ; Boon W; Van Beurden D; Schaart G; Kersten S; Voshol PJ; Wanders RJ; Hesselink MK; Schrauwen P
Obesity (Silver Spring); 2011 Apr; 19(4):792-9. PubMed ID: 20595951
[TBL] [Abstract][Full Text] [Related]
9. Specific Metabolic Profiles and Their Relationship to Insulin Resistance in Recent-Onset Type 1 and Type 2 Diabetes.
Knebel B; Strassburger K; Szendroedi J; Kotzka J; Scheer M; Nowotny B; Müssig K; Lehr S; Pacini G; Finner H; Klüppelholz B; Giani G; Al-Hasani H; Roden M;
J Clin Endocrinol Metab; 2016 May; 101(5):2130-40. PubMed ID: 26829444
[TBL] [Abstract][Full Text] [Related]
10. High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
Wang M; Guo S; He M; Shao X; Feng L; Yu Y; Gong W; Liu Q; Melnikov V; Wang X; He Z; Jiang L; Chen M; Sun J; Cai J; Zhao Y; Li Y; Tritos NA; Hu Z; Zhang Z
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31930294
[TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry.
Liu X; Zheng P; Zhao X; Zhang Y; Hu C; Li J; Zhao J; Zhou J; Xie P; Xu G
J Proteome Res; 2015 May; 14(5):2322-30. PubMed ID: 25784130
[TBL] [Abstract][Full Text] [Related]
12. Effect of Allium macrostemon on a rat model of depression studied by using plasma lipid and acylcarnitine profiles from liquid chromatography/mass spectrometry.
Chen S; Wei C; Gao P; Kong H; Jia Z; Hu C; Dai W; Wu Y; Xu G
J Pharm Biomed Anal; 2014 Feb; 89():122-9. PubMed ID: 24284228
[TBL] [Abstract][Full Text] [Related]
13. Oral glucose tolerance test in Italian overweight/obese children and adolescents results in a very high prevalence of impaired fasting glycaemia, but not of diabetes.
Cambuli VM; Incani M; Pilia S; Congiu T; Cavallo MG; Cossu E; Sentinelli F; Mariotti S; Loche S; Baroni MG
Diabetes Metab Res Rev; 2009 Sep; 25(6):528-34. PubMed ID: 19496065
[TBL] [Abstract][Full Text] [Related]
14. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes.
Ha CY; Kim JY; Paik JK; Kim OY; Paik YH; Lee EJ; Lee JH
Clin Endocrinol (Oxf); 2012 May; 76(5):674-82. PubMed ID: 21958081
[TBL] [Abstract][Full Text] [Related]
15. Metabolite profiling in identifying metabolic biomarkers in older people with late-onset type 2 diabetes mellitus.
Tam ZY; Ng SP; Tan LQ; Lin CH; Rothenbacher D; Klenk J; Boehm BO; ;
Sci Rep; 2017 Jun; 7(1):4392. PubMed ID: 28663594
[TBL] [Abstract][Full Text] [Related]
16. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease.
Saiki S; Hatano T; Fujimaki M; Ishikawa KI; Mori A; Oji Y; Okuzumi A; Fukuhara T; Koinuma T; Imamichi Y; Nagumo M; Furuya N; Nojiri S; Amo T; Yamashiro K; Hattori N
Sci Rep; 2017 Aug; 7(1):7328. PubMed ID: 28779141
[TBL] [Abstract][Full Text] [Related]
17. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
[TBL] [Abstract][Full Text] [Related]
18. A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome.
Nauck MA; Meier JJ; Wolfersdorff AV; Tillil H; Creutzfeldt W; Köbberling J
Acta Diabetol; 2003 Dec; 40(4):163-72. PubMed ID: 14740275
[TBL] [Abstract][Full Text] [Related]
19. A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease.
Chang Y; Gao XQ; Shen N; He J; Fan X; Chen K; Lin XH; Li HM; Tian FS; Li H
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7433-7441. PubMed ID: 32706083
[TBL] [Abstract][Full Text] [Related]
20. Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance.
Nowak C; Hetty S; Salihovic S; Castillejo-Lopez C; Ganna A; Cook NL; Broeckling CD; Prenni JE; Shen X; Giedraitis V; Ärnlöv J; Lind L; Berne C; Sundström J; Fall T; Ingelsson E
Sci Rep; 2018 Jun; 8(1):8691. PubMed ID: 29875472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
